跳至主要内容
临床试验/IRCT2016012826168N1
IRCT2016012826168N1已完成未知

Evaluation of efficacy of Riluzole compared with placebo in the treatment of Methamphetamine dependence: A randomized, double-blind, placebo-controlled trial

Vice chancellor for research, Tehran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Dependence to Methamphetamine according to DSM-IV criteria, consent and commitment for treatment cooperation, age above 18 and under 65. Exclusion criteria: Past history of sensitivity to Riluzole? past history of structural or functional liver disease or abnormal liver function tests (Ast, Alt). 5fold increase in liver enzymes test (Ast,Alt) or jaundice? abnormal renal function tests at the beginning of the study? interstitial lung disease or hypersensitive pneumonitis? neutropenia? pregnancy or lactation? developing psychiatric disorders or previous neurologic disorders like psychosis? bipolar disorders? major depression, tic disorders? Tourette's syndrome or any psychiatric disorders that need medical therapy or makes dependency to addiction therapy complicated; developing significant clinical cardiovascular disorders? physical exam or electrocardiography? family history of disability or premature cardiovascular mortality in first degree relatives? past history of severe untreated physical disabilities? abnormal vital signs.

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Tehran University of Medical Sciences

相似试验